REGN7508 to prevent blood clots in adults with solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3, randomized, placebo-controlled study comparing REGN7508 to placebo for prevention of cancer-associated thrombosis in adults with locally advanced or metastatic solid tumors who are at increased clotting risk. Eligible participants have a Khorana score of 2 or greater or a tumor genetic variant linked to higher VTE risk and an ECOG performance status of 0–2. Participants receive REGN7508 or placebo while receiving anticancer therapy (or shortly before/after such therapy) and are monitored for new venous or arterial thromboembolic events, adverse events, drug levels in blood, and anti-drug antibodies. The trial is being conducted at multiple clinical research sites in the United States.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
2. Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
3. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention

Key Exclusion Criteria:

1. Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
2. Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
3. Has a primary brain tumor or brain metastases as described in the protocol
4. Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
5. Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Where it's running

• Bioresearch Partner- Hialeah Hospital
  Hialeah, Florida, United States Recruiting
• Helios Clinical Research
  North Miami Beach, Florida, United States Recruiting
• Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting
• LTD High Technology Hospital Medcenter
  Batumi, Adjara, Georgia Recruiting
• Krystyna Kiel Oncology Center
  Kutaisi, Imereti, Georgia Recruiting

Study contacts

• Study coordinator: Clinical Trials Administrator
• Email: clinicaltrials@regeneron.com
• Phone: 844-734-6643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ALN-CIDEB in adults with MASLD to see if it helps the liver

  This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.

  Recruiting at 4 sites Phase 3 Regeneron Pharmaceuticals · Miami, Florida and 3 other locations · NCT07854782

• Olatorepatide vs placebo for adults with moderate-to-severe hidradenitis suppurativa who are overweight

  This study tests whether olatorepatide can help people with hidradenitis suppurativa who are overweight or obese.

  Recruiting Phase 2 Regeneron Pharmaceuticals · The Bronx, New York · NCT07830329

• Three antibodies plus heparin in adults with end-stage kidney disease on dialysis

  This study tests three investigational antibodies (REGN9933, REGN7508, REGN9533) in adults with end-stage kidney disease on hemodialysis who are already using heparin to prevent clots.

  Recruiting Phase 1 Regeneron Pharmaceuticals · Ghent, Oost-Vlaanderen · NCT07759167

• REGN17235 for CCUS and LR-MDS with SF3B1 mutation

  This study tests REGN17235 in adults with CCUS or LR-MDS carrying an SF3B1 mutation to see if it is safe and tolerable and to get early signals of efficacy.

  Recruiting at 2 sites Phase 1 Regeneron Pharmaceuticals · Ghent and 1 other locations · NCT07753148

• Blood-clot prevention with REGN7508 and REGN9933 in people with PICC lines

  This study tests whether REGN7508 and REGN9933 can help prevent blood clots in people who have a PICC line.

  Recruiting Phase 3 Regeneron Pharmaceuticals · Tbilisi · NCT07697599

• Olatorepatide in adults who are overweight or have obesity (without diabetes) test of safety and dosing

  This study tests olatorepatide versus placebo to see if it can safely help adults who are overweight or obese lose weight at different doses.

  Recruiting at 21 sites Phase 2 Regeneron Pharmaceuticals · Mobile, Alabama and 20 other locations · NCT07685808

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.